Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued (2016 - 2025)

Historic Shares Issued for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $11.8 million.

  • Viridian Therapeutics, Inc.\DE's Shares Issued fell 9690.52% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.8 million, marking a year-over-year decrease of 8300.42%. This contributed to the annual value of $453.7 million for FY2024, which is 26272.78% up from last year.
  • Viridian Therapeutics, Inc.\DE's Shares Issued amounted to $11.8 million in Q3 2025, which was down 9690.52% from $763000.0 recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Shares Issued high stood at $382.7 million for Q3 2024, and its period low was $4000.0 during Q2 2022.
  • Its 5-year average for Shares Issued is $50.5 million, with a median of $6.9 million in 2023.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Shares Issued crashed by 9994.73% in 2022, and later soared by 5372573.84% in 2024.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Shares Issued stood at $32.4 million in 2021, then dropped by 22.57% to $25.1 million in 2022, then skyrocketed by 359.57% to $115.3 million in 2023, then plummeted by 39.36% to $69.9 million in 2024, then crashed by 83.06% to $11.8 million in 2025.
  • Its Shares Issued stands at $11.8 million for Q3 2025, versus $763000.0 for Q2 2025 and $2.3 million for Q1 2025.